Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer
S.-A. Im, K. Kalinsky, K.L. Jhaveri, S. Loibl, N. Turner, C. Saura, P. Schmid, S. Loi, E. Hamilton, N. Karadurmus, S. Wang, A.A. Awan, E.M. Ciruelos, C.-F. Chung, E. Thanopoulou, N. Shankar, S. Lim, Y. Jin, C. Song, D. Juric · 2026
Read Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer by S.-A. Im, K. Kalinsky, K.L. Jhaveri, S. Loibl, N. Turner, C. Saura, P. Schmid, S. Loi, E. Hamilton, N. Karadurmus, S. Wang, A.A. Awan, E.M. Ciruelos, C.-F. Chung, E. Thanopoulou, N. Shankar, S. Lim, Y. Jin, C. Song, D. Juric (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13235453.txt.
Description
S.-A. Im and a large trial team analysed in 2026 side effects of a three-drug combination for advanced breast cancer. The INAVO120 trial added inavolisib to two established medicines for tumours carrying a specific gene mutation and resisting hormone therapy. Earlier results showed longer survival without progression and longer overall survival for the combination. Safety analysis focused on high blood sugar, mouth inflammation, rash, and diarrhoea.
High blood sugar appeared within about a week for many patients and most often led to dose pauses among the four problems. Standard supportive medicines managed each side effect, from metformin for blood sugar to a steroid mouthwash for mouth sores. Very few patients stopped the new drug permanently because of any single side effect listed. Patterns looked broadly similar across regions and age groups in the trial. The authors judge the safety profile consistent with longer-term experience and manageable in practice.
Catalog record
| CREATOR | S.-A. Im, K. Kalinsky, K.L. Jhaveri, S. Loibl, N. Turner, C. Saura, P. Schmid, S. Loi, E. Hamilton, N. Karadurmus, S. Wang, A.A. Awan, E.M. Ciruelos, C.-F. Chung, E. Thanopoulou, N. Shankar, S. Lim, Y. Jin, C. Song, D. Juric |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |